Overlooked by IPO investors, Jhunjhunwala’s Star Health scores first ‘BUY’ rating

“We are of the view that investors should not be deterred by high valuations, which are rightfully anchored to Star Health’s early unassailable position in a high-growth industry,” says Avinash Singh, an analyst with Emkay Global, in a note with his co-author Shrishti Jagati.